Grade 3-4 immune-related adverse events induced by immune checkpoint inhibitors in non-small-cell lung cancer (nsclc) patients are correlated with better outcome: a real-life observational study

HIGHLIGHTS

• who: Nadia Guezour and colleagues from the Hôpital Bichat-Claude Bernard, Rue Henri Huchard, Paris, FranceBichat-Claude Bernard University Hospital and in a community hospital, Saint-Joseph Foundation have published the research work: Grade 3-4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study, in the Journal: (JOURNAL) of 31/Dec/2019
• what: Immunotherapy has become a standard treatment for advanced NSCLC.
• how: Anonymized data were analyzed using IBM SPSS Statistics for Windows . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.